S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Better Than Oil Stocks (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Better Than Oil Stocks (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Better Than Oil Stocks (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Better Than Oil Stocks (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Better Than Oil Stocks (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Better Than Oil Stocks (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Better Than Oil Stocks (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Better Than Oil Stocks (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain

Kura Oncology (KURA) Stock Forecast & Price Target

$20.25
+0.66 (+3.37%)
(As of 02/23/2024 ET)

Kura Oncology Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$28.28
39.64% Upside
High Forecast$37.00
Average Forecast$28.28
Low Forecast$10.50
TypeCurrent Forecast
2/24/23 to 2/24/24
1 Month Ago
1/25/23 to 1/25/24
3 Months Ago
11/26/22 to 11/26/23
1 Year Ago
2/24/22 to 2/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$28.28$27.17$27.31$30.67
Predicted Upside39.64% Upside141.55% Upside144.74% Upside107.79% Upside
Get Kura Oncology Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.


KURA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KURA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Kura Oncology Stock vs. The Competition

TypeKura OncologyMedical CompaniesS&P 500
Consensus Rating Score
2.88
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside39.64% Upside2,461.82% Upside7.48% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/31/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Outperform ➝ Market Outperform$22.00 ➝ $32.00+59.60%
12/22/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$26.00+106.84%
12/8/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$32.00+186.48%
11/3/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$40.00 ➝ $37.00+314.33%
9/7/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$30.00+203.95%
8/11/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$31.00+180.80%
7/27/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Perform$10.50+5.85%
6/12/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$24.00 ➝ $25.00+86.29%
5/16/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$31.00+147.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:10 AM ET.












KURA Price Target - Frequently Asked Questions

What is Kura Oncology's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Kura Oncology stock is Moderate Buy based on the current 1 hold rating and 7 buy ratings for KURA. The average twelve-month price prediction for Kura Oncology is $28.28 with a high price target of $37.00 and a low price target of $10.50. Learn more on KURA's analyst rating history.

Do Wall Street analysts like Kura Oncology more than its competitors?

Analysts like Kura Oncology more than other Medical companies. The consensus rating score for Kura Oncology is 2.88 while the average consensus rating score for medical companies is 2.68. Learn more on how KURA compares to other companies.

Does Kura Oncology's stock price have much upside?

According to analysts, Kura Oncology's stock has a predicted upside of 133.86% based on their 12-month stock forecasts.

What analysts cover Kura Oncology?

Kura Oncology has been rated by HC Wainwright, JMP Securities, and Mizuho in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:KURA) was last updated on 2/24/2024 by MarketBeat.com Staff